Effects of the glucagon-like polypeptide-1 analogue (Val8)GLP-1 on learning, progenitor cell proliferation and neurogenesis in the C57B/16 mouse brain

Brain Research

Volumn 1473, Issue , 2012, Pages 204-213

  McGovern, Stephen F J ^a   Hunter, Kerry ^a   Hölscher, Christian ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Alzheimer's disease; Cognition; Diabetes; Incretin; Insulin; Neurodegenerative disease; Neurogenesis

Indexed keywords

(VAL 8)GLUCAGON LIKE POLYPEPTIDE 1; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; UNCLASSIFIED DRUG; VALINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TISSUE; CELL PROLIFERATION; CONTROLLED STUDY; DENTATE GYRUS; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; EXPLORATORY BEHAVIOR; GLUCOSE BLOOD LEVEL; HIPPOCAMPUS; INSULIN SENSITIVITY; LEARNING; LOCOMOTION; MALE; MAZE TEST; MEMORY; MOTOR ACTIVITY; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; RECOGNITION; STEM CELL;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUCAGON-LIKE PEPTIDE 1; IMMUNOHISTOCHEMISTRY; LEARNING; MALE; MICE; MICE, INBRED C57BL; NEURAL STEM CELLS; NEUROGENESIS; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY;

MUS; RATTUS;

EID: 84865521108     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2012.07.029     Document Type: Article

References (34)

1. T. Abbas, E. Faivre, and C. Hlscher Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer's disease Behav. Brain Res. 205 2009 265 271
2. L. Bondolfi, M. Calhoun, F. Ermini, H.G. Kuhn, K.H. Wiederhold, L. Walker, M. Staufenbiel, and M. Jucker Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice J. Neurosci. 22 2002 515 522
3. M.J. During, L. Cao, D.S. Zuzga, J.S. Francis, H.L. Fitzsimons, X. Jiao, R.J. Bland, M. Klugmann, W.A. Banks, D.J. Drucker, and C.N. Haile Glucagon-like peptide-1 receptor is involved in learning and neuroprotection Nat. Med. 9 2003 1173 1179
4. V.A. Gault, and C. Holscher GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid Eur. J. Pharmacol. 587 2008 112 117
5. S. Gengler, P. McClean, R. McCurtin, V. Gault, and C. Holscher Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice Neurobiol. Aging 33 2012 265 276
6. B.D. Green, K.S. Lavery, N. Irwin, F.P. O'Harte, P. Harriott, B. Greer, C.J. Bailey, and P.R. Flatt Novel GLP-1 analogue (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta cell function after 3 weeks daily administration in obese diabetic (ob/ob) mice J. Pharmacol. Exp. Ther. 318 2006 914 921
7. D.A. Greenberg, and K. Jin Neurodegeneration and neurogenesis: focus on Alzheimer's disease Curr. Alzheimer Res. 3 2006 25 28
8. A. Hamilton, S. Patterson, D. Porter, V.A. Gault, and C. Holscher Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain J. Neurosci. Res. 89 2011 481 489
9. E.L. Hargreaves, and D.P. Cain Hyperactivity, hyper-reactivity, and sensimotor deficits induced by low doses of the N-methyl-d-aspartate non-competitive channel blocker MK801 Behav. Brain Res. 47 1992 23 33
10. A. Harkavyi, A. Abuirmeileh, R. Lever, A.E. Kingsbury, C.S. Biggs, and P.S. Whitton Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease J. Neuroinflammation 5 2008 19
11. T. Himeno, H. Kamiya, K. Naruse, N. Harada, N. Ozaki, Y. Seino, T. Shibata, M. Kondo, J. Kato, T. Okawa, A. Fukami, Y. Hamada, N. Inagaki, D.J. Drucker, Y. Oiso, and J. Nakamura Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice Diabetes 60 2011 2397 2406
12. C. Holscher Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease Biochem. Soc. Trans. 39 2011 891 897
13. C. Hlscher, L. McGlinchey, and M.J. Rowan l-AP4 (l-()-2-amino-4- phosphonobutyric acid) induced impairment of spatial learning in the rat is antagonized by MAP4 ((S)-2-amino-2-methy l-4-phosphonobutanoic acid) Behav. Brain Res. 81 1996 69 79
14. J.J. Holst Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors Expert Opin. Emerg. Drugs 9 2004 155 166
15. K. Hunter, and C. Holscher Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis BMC Neurosci. 13 2012 33 38
16. C. Hyun Lee, B. Yan, K.Y. Yoo, J.H. Choi, S.H. Kwon, S. Her, Y. Sohn, I.K. Hwang, J.H. Cho, Y.M. Kim, and M.H. Won Ischemia-induced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia J. Neurosci. Res. 89 2011 1103 1113
17. A.J. Kastin, V. Akerstrom, and W. Pan Interactions of glucagon-like peptide-1 (GLP-1) with the bloodbrain barrier J. Mol. Neurosci. 18 2002 7 14
18. A.J. Kastin, and V. Akerstrom Entry of exendin-4 into brain is rapid but may be limited at high doses Int. J. Obes. Relat. Metab. Disord. 27 2003 313 318
19. H. Li, C.H. Lee, K.Y. Yoo, J.H. Choi, O.K. Park, B.C. Yan, K. Byun, B. Lee, I.K. Hwang, and M.H. Won Chronic treatment of exendin-4 affects cell proliferation and neuroblast differentiation in the adult mouse Hippocampal dentate gyrus Neurosci. Lett. 19 2010 1205 1219
20. L. Li, Z.F. Zhang, C. Holscher, C. Gao, Y.H. Jiang, and Y.Z. Liu (Val(8)) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains Eur. J. Pharmacol 2011
21. Y. Li, T. Perry, M.S. Kindy, B.K. Harvey, D. Tweedie, H.W. Holloway, K. Powers, H. Shen, J.M. Egan, K. Sambamurti, A. Brossi, D.K. Lahiri, M.P. Mattson, B.J. Hoffer, Y. Wang, and N.H. Greig GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism Proc. Nat. Acad. Sci. USA 2009
22. J.G. Lim, J.J. Lee, S.H. Park, J.H. Park, S.J. Kim, H.C. Cho, W.K. Baek, D.K. Kim, and D.K. Song Glucagon-like peptide-1 protects NSC-34 motor neurons against glucosamine through Epac-mediated glucose uptake enhancement Neurosci. Lett. 479 2010 13 17
23. J.A. Lovshin, and D.J. Drucker Incretin-based therapies for type 2 diabetes mellitus Nat. Rev. Endocrinol. 5 2009 262 269
24. J.A. Luchsinger, M.X. Tang, S. Shea, and R. Mayeux Hyperinsulinemia and risk of Alzheimer disease Neurology 63 2004 1187 1192
25. P. McClean, V. Parthsarathy, E. Faivre, and C. Hlscher The diabetes drug Liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease J. Neurosci. 31 2011 6587 6594
26. A.M. Moloney, R.J. Griffin, S. Timmons, R. O'Connor, R. Ravid, and C. O'Neill Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling Neurobiol. Aging 31 2010 224 243
27. T. Ohara, Y. Doi, T. Ninomiya, Y. Hirakawa, J. Hata, T. Iwaki, S. Kanba, and Y. Kiyohara Glucose tolerance status and risk of dementia in the community: the Hisayama Study Neurology 77 2011 1126 1134
28. T. Perry, D.K. Lahiri, D. Chen, J. Zhou, K.T. Shaw, J.M. Egan, and N.H. Greig A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells J. Pharmacol. Exp. Ther. 300 2002 958 966
29. T. Perry, H.W. Holloway, A. Weerasuriya, P.R. Mouton, K. Duffy, J.A. Mattison, and N.H. Greig Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy Exp. Neurol. 203 2007 293 301
30. M. Plastino, A. Fava, D. Pirritano, P. Cotronei, N. Sacco, T. Sperli, A. Spano, D. Gallo, P. Mungari, D. Consoli, and D. Bosco Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2 J. Neurol. Sci. 288 2010 112 116
31. A. Vella, P. Shah, A.S. Reed, A.S. Adkins, R. Basu, and R.A. Rizza Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans Diabetologia 45 2002 1410 1415
32. N. Vrang, and P.J. Larsen Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides Prog. Neurobiol. 92 2010 442 462
33. X.H. Wang, L. Li, C. Holscher, Y.F. Pan, X.R. Chen, and J.S. Qi Val8-glucagon-like peptide-1 protects against Abeta1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats Neuroscience 170 2010 1239 1248
34. T.R. Yamasaki, M. Blurton-Jones, D.A. Morrissette, M. Kitazawa, S. Oddo, and F.M. LaFerla Neural stem cells improve memory in an inducible mouse model of neuronal loss J. Neurosci. 27 2007 11925 11933